The Mycoplasma Testing Market is being driven by the increasing need for rapid and reliable contamination detection throughout pharmaceutical and biotechnology manufacturing.

One of the most important market trends is the migration from traditional culture-based methods toward molecular testing. Quantitative PCR currently accounts for a significant portion of testing activity because of its speed, sensitivity, and established regulatory acceptance. Digital PCR is also gaining attention because of its ability to provide highly sensitive detection and absolute quantification.

The growth of cell and gene therapies is another major market trend. As more advanced therapies move through clinical development and commercialization, manufacturers require mycoplasma testing at multiple stages, including cell-bank characterization, in-process testing, and final product release.

Outsourcing is also influencing market development. Contract manufacturing organizations, contract research organizations, and specialized testing laboratories are increasingly providing mycoplasma testing services to pharmaceutical and biotechnology companies.

Cloud-based laboratory management, automation, sample-to-answer molecular systems, and data analytics are further improving testing workflows and laboratory efficiency.

Regionally, North America remains a leading market, while Asia-Pacific is expected to demonstrate particularly strong growth through 2035. Increasing investments in biopharmaceutical manufacturing facilities and laboratory infrastructure are creating new opportunities for testing technology providers.